SyncThink Receives Further FDA Clearance for Concussion Aid
EYE-SYNC previously received Breakthrough Device Designation from the FDA in 2019, following the initial clearance and commercialisation of the technology platform in 2017.
SyncThink founder and Stanford University professor Jam Ghajar, MD, PhD, said: “After a decade of clinical research, 30 publications, and 16 patents, we are pleased to formally extend EYE-SYNC’s indications to the many providers who will benefit from rapid, objective diagnostic technology. Concussion is a complex condition and a challenge for many clinicians to manage, so we hope that by offering highly accurate diagnostic tools and proven algorithms, we will help providers and their patients identify the most effective and appropriate treatment.”
In support of the application, SyncThink enrolled 1,655 pediatric and adult subjects into a clinical study that collected comprehensive patient and concussion related data for over one year. Utilising this information, SyncThink implemented proprietary algorithms and deep learning models to identify a positive or negative indication of concussion. The study showed that EYE-SYNC demonstrated sensitivity above 82% and specificity above 93%, thereby providing clinicians with significant and actionable data when evaluating individuals with concussion.
SyncThink chief clinical officer Scott Anderson, said: “The outcome of this study very clearly shows the effectiveness of our technology at detecting concussion, and definitively demonstrates the clinical utility of EYE-SYNC. It also shows that the future of concussion diagnosis is no longer purely symptom based, but that of a technology driven multi-modal approach.”
The EYE-SYNC technology utilises a series of 60 second eye tracking assessments, neurocognitive batteries, symptom inventories, and standardised patient inventories to identify the type and severity of dysfunction after concussion. The platform generates customisable and interpretive reports that support clinical decision making and offers visual and vestibular therapies to remedy deficits and monitor improvement over time.
Seen on Med-Tech Innovation News: Article Link